Samuel Takvorian
Leadership MD, MSHP Associate Director, PC3I & Director, Program in Patient-Generated Health Data, PC3IAssistant Professor, Hematology and Oncology, Perelman School of Medicine
Samuel Takvorian, MD, MSHP, is an Associate Director and Innovation Faculty member at the Penn Center for Cancer Care Innovation (PC3I) as well as the Director of the Program in Patient-Generated Health Data at PC3I. Dr. Takvorian’s work focuses on clinical transformation and innovation in cancer care delivery. He is passionate about answering questions pertaining to the value of cancer care, encompassing rigorous measurement of both traditional and patient-reported outcomes, as well as the costs of care; and to improving the implementation of research findings into routine practice. His clinical focus is genitourinary malignancies.
Dr. Takvorian is an Assistant Professor in the Division of Hematology and Oncology at the University of Pennsylvania. He graduated from Harvard Medical School and completed his Internal Medicine residency at Brigham and Women’s Hospital in Boston. He completed fellowship in Hematology and Oncology at the University of Pennsylvania, where he served as Chief Fellow and earned a Master of Science in Health Policy Research.
His interest in healthcare delivery dates back to an AmeriCorps year, leading health advocacy efforts in a community health center during the rollout of Massachusetts health reform. Later work at Harvard Business School and the Alliance for Health Reform in Washington, DC inspired him towards a career in cancer care delivery and health services research. He has received multiple mentorship awards for his commitment to medical education, and was awarded the Jane Alavi Award for clinical excellence in fellowship.
Samuel’s Work
Impact of Insurance Coverage on Clinical Trial Enrollment
- Health Equity
- Payment Models & Affordability
Increasing Rates of Serious Illness Conversations through Patient and Clinician Nudges
- Augmented & Artificial Intelligence
- Behavior Change
- Clinical Transformation
- Health Equity
Nudges Informed by Behavioral Economics to Increase Utilization of Higher-Value Cancer Drugs
- Behavior Change
- Payment Models & Affordability